Ministerstvo financí státu Aljaška ve třetím čtvrtletí snížilo svůj podíl ve společnosti Glaukos o 48,6 % prodejem 9 393 akcií; nyní drží 9 950 akcií v hodnotě 1,633 milionu USD.
State of Alaska Department of Revenue lowered its stake in Glaukos Corporation (NYSE:GKOS – Free Report) by 48.6% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 9,950 shares of the medical instruments supplier’s stock after selling 9,393 shares during the period. State of Alaska Department of Revenue’s holdings in Glaukos were worth $1,633,000 as of its most recent filing with the SEC.
Several other institutional investors also recently modified their holdings of the stock. Allworth Financial LP bought a new stake in shares of Glaukos during the 2nd quarter worth $28,000. CoreCap Advisors LLC acquired a new position in shares of Glaukos in the 3rd quarter worth $33,000. Fortitude Family Office LLC acquired a new stake in shares of Glaukos during the third quarter worth $36,000. Parallel Advisors LLC raised its position in shares of Glaukos by 159.2% during the first quarter. Parallel Advisors LLC now owns 368 shares of the medical instruments supplier’s stock worth $40,000 after purchasing an additional 226 shares during the period. Finally, IFP Advisors Inc raised its position in shares of Glaukos by 523.4% during the second quarter. IFP Advisors Inc now owns 293 shares of the medical instruments supplier’s stock worth $41,000 after purchasing an additional 246 shares during the period. Institutional investors own 99.04% of the company’s stock.
Glaukos Price Performance NYSE GKOS opened at $166.98 on Tuesday. Glaukos Corporation has a twelve month low of $73.16 and a twelve month high of $191.62. The company has a current ratio of 5.04, a quick ratio of 4.46 and a debt-to-equity ratio of 0.10. The firm’s 50 day moving average price is $172.08 and its two-hundred day moving average price is $148.69.
Glaukos (NYSE:GKOS – Get Free Report) last announced its earnings results on Wednesday, July 29th. The medical instruments supplier reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.07. The company had revenue of $185.61 million for the quarter, compared to the consensus estimate of $150.93 million. Glaukos had a negative net margin of 30.68% and a negative return on equity of 6.37%. The company’s revenue was up 49.6% on a year-over-year basis. During the same period in the previous year, the business earned ($0.24) EPS. As a group, sell-side analysts forecast that Glaukos Corporation will post -0.32 earnings per share for the current year. Insiders Place Their Bets In related news, CFO Alex R. Thurman sold 20,000 shares of the stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $180.13, for a total value of $3,602,600.00. Following the completion of the sale, the chief financial officer directly owned 43,906 shares of the company’s stock, valued at approximately $7,908,787.78. This represents a 31.30% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Joseph Gilliam sold 60,000 shares of the stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $179.74, for a total value of $10,784,400.00. Following the completion of the sale, the chief operating officer directly owned 72,588 shares of the company’s stock, valued at approximately $13,046,967.12. This represents a 45.25% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 83,025 shares of company stock worth $14,950,006. 5.90% of the stock is owned by corporate insiders.
Analyst Ratings Changes A number of equities analysts recently weighed in on the company. Stifel Nicolaus increased their price target on Glaukos from $175.00 to $190.00 and gave the company a “buy” rating in a research report on Thursday, July 30th. Truist Financial lifted their price target on Glaukos from $180.00 to $215.00 and gave the stock a “buy” rating in a research note on Thursday, July 30th. UBS Group initiated coverage on Glaukos in a report on Tuesday, July 28th. They set a “neutral” rating and a $150.00 price objective on the stock. Jefferies Financial Group boosted their price objective on Glaukos from $190.00 to $210.00 and gave the stock a “buy” rating in a report on Tuesday, September 22nd. Finally, Needham & Company LLC upped their price objective on shares of Glaukos from $150.00 to $201.00 and gave the company a “buy” rating in a research note on Thursday, July 30th. Thirteen investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $181.43.
Check Out Our Latest Report on Glaukos
Glaukos Profile (Free Report)
Glaukos Corporation is an ophthalmic medical-technology company focused on developing and commercializing therapies for chronic eye diseases. The company’s principal areas of focus include glaucoma, corneal disorders and retinal diseases, with an emphasis on treatments that may reduce reliance on conventional pharmaceuticals or more invasive surgical procedures.
Glaukos is best known for its micro-invasive glaucoma surgery (MIGS) products, including the iStent family of implantable devices used to help lower intraocular pressure in patients with glaucoma.
Featured Stories Five stocks we like better than Glaukos Tesla’s Roadster Reveal Hints at 2 Much Bigger Moves The AI Sell-Off Continues—These 3 Stocks Keep Raising Guidance Anyway Mr. Wonderful’s Test for AI Data Center Stocks: Power, Permits, and Tenants Alcoa Beat Earnings, But Can It Escape the Aluminum Bears? Want to see what other hedge funds are holding GKOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Glaukos Corporation (NYSE:GKOS – Free Report).
Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.
Akcie společnosti Glaukos za posledních šest měsíců vzrostly o 36,8 % poté, co její tržby ve 2. čtvrtletí meziročně vzrostly o 50 % na rekordních 185,6 mil. USD.
Key Takeaways Glaukos shares gained 36.8% in six months, outperforming the industry's 8% growth on commercial progress.GKOS posted 50% revenue growth to $185.6 million in Q2 and raised its 2026 sales outlook to $680-$700 million.Epioxa's commercial expansion, positive iDose TR data and pipeline advances boosted GKOS' growth prospects. Glaukos Corporation (GKOS - Free Report) shares have gained 36.8% over the past six months, outperforming its industry’s 8% growth. This reflects growing investor confidence in its ophthalmic treatment portfolio. The rally has been supported by the commercial expansion of iDose TR, progress in launching Epioxa for keratoconus, and clinical and pipeline developments that strengthen the company's long-term growth prospects.
Headquartered in Aliso Viejo, CA, Glaukos develops pharmaceutical and medical technology solutions for glaucoma, corneal disorders and retinal diseases. Its focus on interventional therapies, which seek to improve treatment outcomes while reducing reliance on conventional approaches, provides multiple growth opportunities. Recent commercial milestones, better-than-expected results and encouraging clinical developments have reinforced the investment case for GKOS.
Here, we examine the key factors that may have driven GKOS’ significant share price gains over the past six months.
Image Source: Zacks Investment Research
Commercial Progress With EpioxaThe first catalyst over the past six months was the receipt of a permanent Healthcare Common Procedure Coding System (HCPCS) J-code for Epioxa. Code J2789 became effective on July 1. The product-specific code should help streamline reporting and reimbursement by U.S. payers, supporting market access for the company's epithelium-on corneal cross-linking therapy. This milestone strengthened the commercial launch framework for Epioxa, which treats keratoconus, a progressive, sight-threatening corneal disease.
Earlier this month, Glaukos reported positive three-year results from a Phase 3 extension study of Epioxa. Treated eyes maintained a 1.9-diopter improvement in maximum corneal curvature from baseline, while 29% gained at least two lines of best-corrected visual acuity. The results supported the therapy's potential to deliver durable benefits following a single treatment. The benefits demonstrated in the clinical study may lead to higher adoption of the drug going forward.
Strong Q2 Results and Higher GuidanceGlaukos’ second-quarter results provided a strong fundamental basis for the rally. Consolidated net sales increased approximately 50% year over year to a record $185.6 million, prompting management to raise its 2026 revenue guidance to $680-$700 million from $620-$635 million. The company also recorded lower-than-expected loss during the quarter. Loss per share of 14 cents beat the Zacks Consensus Estimate by 50%.
The U.S. glaucoma franchise generated $118.5 million in sales, up 64% year over year, with iDose TR contributing approximately $74 million. International glaucoma sales increased 17% to $36.6 million, while Corneal Health revenues rose 48% to $30.4 million, including approximately $11 million from Epioxa.
Management also highlighted progress in Epioxa’s commercial rollout, with access pathways covering more than 125 million commercially insured U.S. lives and a treatment-center network spanning locations that serve roughly 85% of the U.S. population. These developments indicate that Glaukos is establishing the infrastructure needed to translate clinical interest into sustained commercial growth.
Positive Clinical Evidence and Pipeline ExpansionGlaukos’ uptrend has also been supported by continued progress with its pipeline development. Successful clinical trials can pave the way for further studies or regulatory approvals, ultimately enabling commercialization and improving sales prospects.
In June, Glaukos announced completion of patient enrollment in the Phase 2 study of GLK-321, an investigational treatment for Demodex blepharitis. The candidate uses the company's iLution platform, which is designed to deliver medication through the eyelid skin rather than conventional eye drops. The enrollment milestone advanced its ocular-surface disease pipeline and expanded the company's opportunities beyond its established glaucoma and corneal franchises.
The momentum continued in July as Glaukos completed patient enrollment in the U.S. pivotal study of PRESERFLO MicroShunt, a minimally invasive drainage device intended to lower intraocular pressure in patients with primary open-angle glaucoma who have not responded adequately to previous medical and surgical treatment. The milestone advanced the program toward a potential FDA marketing submission soon.
Last week, Glaukos announced an exclusive licensing agreement with RevOpsis Therapeutics for RO-104, an investigational tri-specific biologic targeting three angiogenic pathways implicated in retinal diseases. The agreement also provided rights to develop up to four additional retinal biologic candidates, broadening Glaukos' longer-term innovation opportunities.
During the same week, positive Phase 4 results for iDose TR used in conjunction with cataract surgery marked another encouraging clinical milestone. At three months, the combination achieved an 11.1-mmHg reduction in mean diurnal intraocular pressure, compared with 7.4 mmHg for cataract surgery alone. The statistically significant results strengthened the evidence supporting iDose TR across different treatment settings.
Concerns for GKOSGlaukos faces reimbursement uncertainty for iDose TR, as proposed Medicare coverage policies could introduce treatment restrictions and affect adoption. Epioxa's commercialization also faces near-term volatility as providers transition to its permanent J-code, potentially delaying revenue realization.
International operations remain exposed to competitive pressures and reimbursement headwinds in Germany and Switzerland. Moreover, sustained investments in commercial infrastructure and clinical development could delay profitability, while the success of pipeline candidates remains subject to clinical and regulatory risks.
ConclusionGlaukos’ six-month rally reflects a combination of robust revenue growth, raised guidance, improving commercialization prospects and positive clinical developments. Carrying a Zacks Rank #2 (Buy) at present, the company is likely to sustain its uptrend on the back of continued adoption of iDose TR and Epioxa, while its expanding pipeline offers additional long-term opportunities.
A Glance at GKOS’ EstimatesThe Zacks Consensus Estimate for 2026 suggests a 64.4% narrower loss of 32 cents per share while the same for 2027 EPS is pinned at 55 cents per share. In the past 60 days, the Zacks Consensus Estimate for the company's 2026 loss per share has narrowed 8.6%.
Revenues for 2026 are projected to grow 36.2% to $691 million, followed by a 20.9% jump to $835.2 million in 2027.
Other Key PicksSome other top-ranked stocks from the broader medical space are OPKO Health (OPK - Free Report) , Globus Medical (GMED - Free Report) and Merit Medical Systems (MMSI - Free Report) .
OPKO Health, currently flaunting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted loss of 1 cent per share, which surpassed the Zacks Consensus Estimate by 87.5%. Revenues of $163.6 million beat the Zacks Consensus Estimate by 24.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.
OPK has an estimated earnings growth rate of 23.3% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 95.1%.
Globus Medical, currently carrying a Zacks Rank #2, reported a second-quarter 2026 adjusted EPS of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
Merit Medical Systems, carrying a Zacks Rank #2 at present, reported second-quarter 2026 adjusted EPS of $1.19, which beat the Zacks Consensus Estimate by 23.9%. Revenues of $418.8 million surpassed the Zacks Consensus Estimate by 3.5%.
MMSI has an estimated long-term earnings growth rate of 10.4%. MMSI’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 14.1%.
Key Takeaways Glaukos licenses RevOpsis' RO-104 and RevMod platform to expand its retinal disease treatment pipeline.RO-104 targets VEGF-A, VEGF-C and Ang-2, demonstrating superior efficacy in preclinical animal models.The RevMod platform enables GKOS to develop up to four additional biologics for multiple retinal diseases. Glaukos Corporation (GKOS - Free Report) recently announced a licensing agreement with RevOpsis Therapeutics, Inc. to develop and commercialize RO-104, an investigational tri-specific biologic for multiple retinal diseases. The agreement grants Glaukos exclusive rights to RevOpsis’ RevMod platform to discover and develop up to four additional retinal biologic candidates.
Glaukos chairman and CEO Thomas Burns said that the addition of RO-104 and exclusive access to the RevMod platform marks a strategic step in expanding the company’s retinal franchise and complements its existing retinal R&D initiatives. The agreement strengthens GKOS’ pipeline with a first-in-class tri-specific biologic and offers an opportunity to develop additional therapeutic candidates for multiple retinal diseases. Management believes RO-104’s ability to inhibit three angiogenic pathways simultaneously could provide significant treatment advantages for retinal vascular diseases while supporting the company’s long-term innovation strategy in the retina market.
GKOS Stock Trend Following the NewsFollowing the announcement, GKOS stock lost 6.3% at yesterday’s close. Year to date, the stock gained 42.8%, outperforming the industry’s 6.9% decline and the S&P 500’s 13.9% gain.
The agreement could strengthen GKOS’ long-term growth prospects by expanding its presence in retinal therapeutics beyond its existing ophthalmic business. Access to a differentiated biologic candidate and a discovery platform may diversify its future product opportunities and create additional avenues for growth. If RO-104 demonstrates clinical success, it could help Glaukos compete in multiple retinal disease markets, while the platform’s additional candidates could provide further pipeline value over time.
GKOS currently has a market capitalization of $10.16 billion.
Image Source: Zacks Investment Research
More on the NewsRO-104 is designed as a first-in-class tri-specific biologic with a high-concentration formulation that inhibits VEGF-A, VEGF-C and Ang-2, three clinically validated pathways involved in the progression of retinal vascular diseases. It is being developed for neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), diabetic retinopathy (DR) and retinal vein occlusion (RVO). In established preclinical animal models, the candidate has demonstrated superior efficacy compared with approved anti-VEGF therapies.
Beyond RO-104, the license gives Glaukos exclusive rights to the RevMod platform across geographic atrophy, DME, DR, RVO and nAMD, enabling the discovery and development of up to four additional next-generation retinal biologics. The financial terms of the agreement were not disclosed. Clinical development and regulatory progress will be important milestones in determining the commercial potential of these programs.
RevOpsis management views the agreement as validation of its RevMod platform and its strategy of developing next-generation multispecific therapies for retinal diseases. The company believes Glaukos’ ophthalmology expertise and commercialization capabilities will help advance RO-104 and expand the platform into a broader portfolio of potential retinal treatments.
Industry Prospects Favoring the MarketAccording to Fortune Business Insights, the global retinal biologics market is estimated to reach $27.25 billion in 2026 and is projected to grow at a CAGR of 8% through 2034.
Factors like rising rates of retinal disorders, an aging population, increasing diabetes prevalence and advances in targeted biologic therapies are expected to support market growth.
Other NewsGlaukos recently announced positive Phase 3 extension study results for Epioxa, demonstrating durable benefits three years after a single treatment. Patients showed sustained corneal improvement, meaningful visual acuity gains and a favorable safety profile, supporting Epioxa’s potential to provide long-term keratoconus stabilization.
Last month, Glaukos launched its “Could it be KC?” campaign, partnering with NBA champion Stephen Curry to raise awareness of keratoconus, a progressive corneal disease. Curry will share his personal experience to encourage early detection, proactive eye care and timely diagnosis, with educational initiatives targeting patients, families and underserved communities.
GKOS’ Zacks Rank & Other Key PicksCurrently, GKOS carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks from the broader medical space are OPKO Health (OPK - Free Report) , Globus Medical (GMED - Free Report) and Merit Medical Systems (MMSI - Free Report) .
OPKO Health, currently flaunting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted loss of 1 cent per share, which surpassed the Zacks Consensus Estimate by 87.5%. Revenues of $163.6 million beat the Zacks Consensus Estimate by 24.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.
OPK has an estimated earnings growth rate of 23.3% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 95.1%.
Globus Medical, currently carrying a Zacks Rank #2, reported a second-quarter 2026 adjusted EPS of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
Merit Medical Systems, carrying a Zacks Rank #2 at present, reported second-quarter 2026 adjusted EPS of $1.19, which beat the Zacks Consensus Estimate by 23.9%. Revenues of $418.8 million surpassed the Zacks Consensus Estimate by 3.5%.
MMSI has an estimated long-term earnings growth rate of 10.4%. MMSI’s earnings surpassed estimates in the trailing four quarters, the average surprise being 14.1%.
Společnost Glaukos ve studii fáze 4 splnila primární cíl: iDose TR v kombinaci s operací katarakty snížil nitrooční tlak po 3 měsících o 11,1 mmHg, oproti 7,4 mmHg po samotné operaci katarakty.
Study Met Primary Efficacy Endpoint, Demonstrating Statistically Significant Superiority and Clinically Meaningful IOP Reduction vs. Cataract Surgery Alone
iDose TR in Combination with Cataract Surgery Demonstrated Robust Mean IOP Reduction of 11.1 mmHg and Favorable Safety Profile Through 3 Months
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced positive topline results from the Phase 4 prospective, randomized, controlled clinical trial (GLK-101-04) evaluating iDose® TR administered in conjunction with cataract surgery compared to cataract surgery alone in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).
The study achieved its primary efficacy endpoint, with iDose TR demonstrating statistically significant superiority in the reduction of mean diurnal intraocular pressure (IOP) when administered in conjunction with cataract surgery compared to cataract surgery alone. At month 3, subjects undergoing cataract surgery and administration of iDose TR achieved a mean diurnal IOP reduction of 11.1 mmHg from baseline, compared to 7.4 mmHg for subjects undergoing cataract surgery alone, demonstrating statistically significant superiority with a clinically meaningful incremental treatment effect of 3.6 mmHg (p<0.0001). In addition, iDose TR demonstrated statistically significant superiority across all pre-specified secondary responder analyses, further supporting the consistency and robustness of the treatment effect observed in the study.
iDose TR also demonstrated a favorable safety profile through 3 months, with no treated-related adverse events of corneal endothelial cell loss or cystoid macular edema (CME), and no serious corneal adverse events. Overall safety findings were consistent with the well-established safety profile of iDose TR and previous clinical experience.
“We are pleased to announce these positive Phase 4 results, which add to the extensive body of clinical evidence supporting the efficacy, durability, and safety of iDose TR,” said Thomas Burns, Glaukos chairman and chief executive officer. “Importantly, these data further reinforce the versatility of iDose TR across various administration settings, demonstrating its ability to deliver clinically meaningful robust IOP reduction whether administered as a standalone procedure or in conjunction with cataract surgery. iDose TR continues to deliver strong clinical outcomes that provide meaningful benefits for patients, helping to accelerate a broader treatment paradigm shift toward earlier, interventional glaucoma care.”
GLK-101-04 is a Phase 4, prospective, multicenter, randomized, double-masked, parallel-group clinical trial evaluating the efficacy and safety of iDose TR in combination with cataract surgery compared to cataract surgery alone in adults with OAG or OHT. The study randomized 149 study eyes, with 74 eyes assigned to the iDose TR in combination with cataract surgery arm and 75 eyes assigned to the cataract surgery alone arm. The primary endpoint evaluated the change from baseline in mean diurnal IOP at month 3.
iDose TR is a first-of-its-kind, long-duration, intracameral procedural pharmaceutical therapy designed to continuously deliver 24/7 therapeutic levels of a proprietary formulation of travoprost inside the eye for up to three years. iDose TR is intended to improve the standard of care by addressing the ubiquitous patient non-compliance issues and chronic side effects associated with topical glaucoma medications.
For more information about iDose TR and Full Prescribing Information, please visit www.iDoseTRhcp.com.
About Glaukos
Glaukos (www.glaukos.com) is an ophthalmic pharmaceutical and medical technology company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. Glaukos first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching its first MIGS device commercially in 2012. In 2024, Glaukos commenced commercial launch activities for iDose® TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical designed to deliver 24/7 glaucoma drug therapy inside the eye for extended periods of time. Glaukos also markets the only FDA-approved corneal cross-linking therapy utilizing a proprietary bio-activated pharmaceutical for the treatment of keratoconus, a rarely diagnosed corneal disorder. Glaukos continues to successfully develop and advance a robust pipeline of novel, dropless platform technologies designed to meaningfully advance the standard of care and improve outcomes for patients suffering from chronic eye diseases.
About iDose TR (U.S.)
iDose TR (travoprost intracameral implant) is a long duration prostaglandin analog approved for a single administration and indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT). Made from medical-grade titanium, iDose TR is implanted through the trabecular meshwork and back wall of Schlemm's canal, directly into scleral tissue. Once implanted, 75 mcg of a novel, preservative-free, proprietary formulation of travoprost continuously elutes into the anterior chamber via membrane-controlled diffusion, allowing for 24/7 release of medication.
Indication for Use: iDose TR (travoprost intracameral implant) is indicated for the reduction of intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension (OHT).
Dosage and Administration: For ophthalmic intracameral administration. The intracameral administration should be carried out under standard aseptic conditions.
Contraindications: iDose TR is contraindicated in patients with active or suspected ocular or periocular infections, patients with corneal endothelial cell dystrophy (e.g., Fuch’s Dystrophy, corneal guttatae), patients with prior corneal transplantation, or endothelial cell transplants (e.g., Descemet’s Stripping Automated Endothelial Keratoplasty [DSAEK]), patients with hypersensitivity to travoprost or to any other components of the product.
Warnings and Precautions: iDose TR should be used with caution in patients with narrow angles or other angle abnormalities. Monitor patients routinely to confirm the location of the iDose TR at the site of administration. Increased pigmentation of the iris can occur. Iris pigmentation is likely to be permanent.
Adverse Reactions: In controlled studies, the most common ocular adverse reactions reported in 2% to 6% of patients were increases in intraocular pressure, iritis, dry eye, visual field defects, eye pain, ocular hyperaemia, and reduced visual acuity.
Forward-Looking Statements
All statements other than statements of historical facts included in this press release that address activities, events, or developments that we expect, believe, or anticipate will or may occur in the future are forward-looking statements. Although we believe that we have a reasonable basis for forward-looking statements contained herein, we caution you that they are based on current expectations about future events affecting us and are subject to risks, uncertainties, and factors relating to our operations and business environment, all of which are difficult to predict and many of which are beyond our control, that may cause our actual results to differ materially from those expressed or implied by forward-looking statements in this press release. These potential risks and uncertainties include, without limitation, our ability to successfully commercialize our iDose TR, the timing and extent to which obtain regulatory approval for investigational products, our ability to successfully commercialize such products, the ability to obtain and maintain adequate financial coverage and reimbursement for our products, and the continued efficacy and safety profile of our products as might be suggested in this Phase 4 clinical trial. These and other risks, uncertainties, and factors related to Glaukos, and our business are described in detail under the caption “Risk Factors” and elsewhere in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, which was filed with the SEC on July 29, 2026. Our filings with the SEC are available in the Investor Section of our website at www.glaukos.com or at www.sec.gov. In addition, information about the risks and benefits of our products is available on our website at www.glaukos.com. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on the forward-looking statements in this press release, which speak only as of the date hereof. We do not undertake any obligation to update, amend, or clarify these forward-looking statements whether as a result of new information, future events or otherwise, except as may be required under applicable securities law.
Glaukos Corporation (NYSE:GKOS) reported three-year trial results for its non-invasive keratoconus treatment while simultaneously securing an exclusive licensing deal to broaden its pipeline of retinal disease therapies.
Long-Term Phase 3 Success For EpioxaThe ophthalmic healthcare firm released positive topline data from its GLK-202-03 extension study evaluating Epioxa, a novel topical therapy for keratoconus.
Keratoconus is a sight-threatening corneal disorder that remains widely undiagnosed and undertreated throughout the patient population.
Designed as an incision-free alternative to traditional corneal cross-linking, the oxygen-supplemented therapy is bioactivated by pulsed UV light and does not require removing the corneal epithelium, helping to lower procedure pain, streamline administration, and speed patient recovery.
The extension trial monitored 38 study eyes across 35 subjects for up to three years following a single Epioxa treatment, with no further medical interventions administered during the follow-up period.
A total of 92% of participant eyes completed the final three-year assessment visit. Treated eyes maintained a 1.9 diopter improvement in maximum corneal curvature from baseline, proving long-term stabilization and flattening of the cornea.
Furthermore, visual outcomes showed strong performance, with 29% of eyes gaining two or more lines of best-corrected visual acuity and 20% gaining three or more lines.
The treatment maintained a clean safety profile with zero serious adverse events, treatment-related adverse events, or therapy-related patient discontinuations.
Retinal Pipeline Expansion Via Licensing DealGlaukos also announced an exclusive licensing agreement with RevOpsis Therapeutics Inc. to develop and commercialize RO-104, a first-in-class tri-specific biologic.
The high-concentration drug candidate targets several conditions, including neovascular age-related macular degeneration, diabetic macular edema, diabetic retinopathy, and retinal vein occlusion.
The therapeutic simultaneously blocks VEGF-A and VEGF-C while inhibiting Ang-2. Preclinical testing in animal models showed superior performance over existing anti-VEGF therapies.
The deal grants Glaukos exclusive rights to leverage the RevMod platform to develop up to four additional retinal biologics. The financial terms of the transaction were not disclosed.
GKOS Price Action: Glaukos shares were down 10.76% at $153.65 at the time of publication on Thursday, according to Benzinga Pro data.
Glaukos uvedl, že iDose může vytvářet opakovanou léčebnou příležitost, protože pacienti zůstávají na terapii i po opětovném podání. Epioxa mezitím ve 2. čtvrtletí dosáhla tržeb zhruba 11 milionů USD.
Key Takeaways GKOS sees iDose re-administration creating a recurring treatment opportunity as patients remain on therapy.Epioxa generated $11 million in Q2, with broad payer access and treatment-center infrastructure in place.High gross margins and a broad pipeline spanning five platforms support Glaukos' growth prospects. Glaukos Corporation’s (GKOS - Free Report) growth prospects are supported by the continued expansion of interventional glaucoma, growing clinical and commercial synergies between iDose TR and iStent infinite, and the potential for long-term operating leverage. However, physician workflow challenges, infrastructure constraints and margin pressure remain key risks.
Shares of this Zacks Rank #3 (Hold) company have gained 35.9% so far this year against the industry’s 5.5% decline. The S&P 500 Index has increased 13% in the same time frame.
Glaukos, with a market capitalization of $9.43 billion, is a leading ophthalmic medical technology and pharmaceutical company. It has a trailing four-quarter average earnings surprise of 25.87%.
Image Source: Zacks Investment Research
Positive Factors Driving ProspectsiDose re-administration Could Create a Recurring Treatment Opportunity: An important upside for iDose is that re-administration appears to be additive rather than cannibalistic to the initial implant opportunity. Management reported that eligible early commercial patients are successfully undergoing re-administration as their initial iDose therapy wears off, with physicians and patients choosing to remain on the treatment. This creates the potential for a recurring treatment cycle rather than a one-time procedure opportunity.
Future products such as iDose TREX could further strengthen this treatment algorithm. As the installed base of iDose patients expands, successful re-administration could increase lifetime revenue per treated patient while reinforcing physician familiarity with Glaukos’ interventional glaucoma platform.
Epioxa Has the Potential for a Scalable Commercial Infrastructure: Epioxa generated sales worth approximately $11 million in the second quarter, its first full quarter of commercial availability. Glaukos has already established access pathways covering more than 125 million U.S. commercial lives, including the five largest payers. Its O2N treatment-center network reaches locations serving roughly 85% of the U.S. population, with expectations to reach approximately 95% in the pipeline. The permanent J-code became effective on July 1, potentially simplifying reimbursement and claims processing. These infrastructure milestones are important because Epioxa's opportunity depends not only on physician adoption but also on diagnosis, referral, reimbursement and treatment-site availability.
High Gross Margins Provide Significant Operating-Leverage Potential: Glaukos’ business model is showing strong gross-margin leverage as higher-value products become a larger portion of revenues. Gross margin reached approximately 85% in the second quarter, up about 90 basis points sequentially.
Management attributed the improvement primarily to increasing contributions from iDose and Epioxa. The company expects further modest gross-margin accretion, particularly in the fourth quarter, as these products represent a larger share of the revenue mix.
Maintaining an 84-86% full-year gross-margin target while rapidly expanding revenues creates substantial potential for operating leverage, provided commercial and R&D investment grows more slowly than revenues.
Glaukos Is Building Several Growth Platforms Beyond iDose and Epioxa: The company’s longer-term opportunity is supported by a broad pipeline spanning five novel therapeutic platforms and 13 publicly disclosed programs. Within the iDose family, TREX is advancing through Phase IIb/III while TRIO is targeted for FDA approval by the end of 2027. The iLink platform is preparing for a KC screening-device launch later this year and a Phase III program in 2027.
PRESERFLO, Demodex blepharitis and GLK-401 expand the potential into additional glaucoma, ocular-surface and retinal indications. This diversification could reduce dependence on any single product while creating multiple potential catalysts over the next several years.
Key ChallengesiDose Growth Could Moderate After an Exceptionally Strong Q2: Although iDose delivered exceptional second-quarter momentum, management remains cautious about extrapolating the quarter because it represents an early stage of the commercial launch. The company specifically noted that the third quarter is seasonally weaker for ophthalmology procedures and wants to see another one or two quarters before determining whether second-quarter growth represents a sustainable trend.
Consequently, the 2026 iDose outlook of approximately $275-$280 million implies relatively limited sequential growth in the second half. A normalization in procedure volumes, slower account utilization or a more gradual reimbursement ramp up could therefore create quarterly volatility, particularly against the exceptionally strong second-quarter comparison.
Epioxa’s Reimbursement Model Could Pressure Realized Pricing: While Epioxa’s market-access progress is encouraging, its realized economics remain subject to payer mix and mandatory discounts. Management currently views approximately $60,000 as a reasonable starting point for net realized revenue per treatment, incorporating Medicaid pricing, 340B-related volume and other required discounts.
The company is still developing its mix between specialty-pharmacy and buy-and-bill channels. Community practices initially appear more dependent on specialty pharmacy, while larger institutions with reimbursement experience are more comfortable with buy-and-bill. As the commercial model matures, changes in payer mix, contracting and channel utilization could influence Epioxa’s realized revenue per procedure.
International Glaucoma Growth Faces Headwinds: Glaukos' international glaucoma franchise remains healthy, but its growth outlook incorporates several emerging challenges. International glaucoma revenues increased 17% reportedly and 16% on a constant-currency basis in the second quarter. However, management expects new competitive product trialing to create headwinds across certain major markets.
Reimbursement pressure has emerged in Germany and Switzerland, while foreign-exchange tailwinds are expected to disappear over the second half. Although PreserFlo, iStent infinite and broader MIGS adoption should offset some pressure, the combination of competition, reimbursement changes and less favorable currency translation could moderate international growth. Management expects low-to-mid-teens growth for the full year, implying a stronger second-half execution requirement.
Heavy Investment Could Delay Full Profitability Despite Revenue Growth: Glaukos is generating substantial revenue growth, but management continues to prioritize investment in commercial infrastructure and its clinical pipeline. R&D spending increased sequentially as the company expanded its clinical programs, while management reiterated that commercial investments supporting iDose and Epioxa remain a priority.
The company has a clear path toward profitability (given its high gross-margin profile), but the timing depends partly on how aggressively it reinvests incremental revenues into launches and clinical development. With operating expenses now expected to reach approximately $600 million in 2026, stronger-than-expected revenues may not translate proportionately into earnings if management continues to accelerate investments in its growth platforms.
Estimate TrendThe Zacks Consensus Estimate for 2026 revenues is pegged at $689.7 million, indicating a 36% improvement from the previous year’s level.
The consensus mark for loss per share is pinned at 32 cents, indicating a 64.4% improvement from the year-ago reported number. The consensus estimate for loss per share has narrowed 43.9% in the past 60 days.
Stocks to ConsiderSome better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , Veracyte (VCYT - Free Report) and West Pharmaceutical (WST - Free Report) .
Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
Veracyte, currently flaunting a Zacks Rank #1, reported a second-quarter 2026 adjusted EPS of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%.
VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.
West Pharmaceutical, carrying a Zacks Rank #2 at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.
WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 17.4%.
Corient Private Wealth LP ve 2. čtvrtletí nově nakoupila 57 048 akcií společnosti Glaukos za zhruba 7,973 milionu USD. Na konci čtvrtletí držela podíl asi 0,10 %.
Corient Private Wealth LP acquired a new stake in Glaukos Corporation (NYSE:GKOS – Free Report) during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 57,048 shares of the medical instruments supplier’s stock, valued at approximately $7,973,000. Corient Private Wealth LP owned approximately 0.10% of Glaukos at the end of the most recent quarter.
Several other institutional investors have also added to or reduced their stakes in the business. Allworth Financial LP bought a new position in shares of Glaukos during the 2nd quarter valued at $28,000. Los Angeles Capital Management LLC purchased a new stake in Glaukos in the 4th quarter worth approximately $28,000. Larson Financial Group LLC raised its position in shares of Glaukos by 62.0% during the 4th quarter. Larson Financial Group LLC now owns 345 shares of the medical instruments supplier’s stock valued at $39,000 after purchasing an additional 132 shares during the period. Parallel Advisors LLC raised its holdings in Glaukos by 159.2% during the first quarter. Parallel Advisors LLC now owns 368 shares of the medical instruments supplier’s stock valued at $40,000 after acquiring an additional 226 shares during the period. Finally, Farther Finance Advisors LLC grew its position in shares of Glaukos by 111.4% during the fourth quarter. Farther Finance Advisors LLC now owns 408 shares of the medical instruments supplier’s stock worth $46,000 after purchasing an additional 215 shares in the last quarter. 99.04% of the stock is currently owned by hedge funds and other institutional investors.
Glaukos Price Performance Glaukos stock opened at $179.95 on Monday. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.04 and a quick ratio of 4.46. The stock has a market cap of $10.61 billion, a price-to-earnings ratio of -55.37 and a beta of 0.78. The firm has a 50-day moving average of $162.64 and a two-hundred day moving average of $134.10. Glaukos Corporation has a 1 year low of $73.16 and a 1 year high of $191.62.
Glaukos (NYSE:GKOS – Get Free Report) last issued its earnings results on Wednesday, July 29th. The medical instruments supplier reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.07. Glaukos had a negative net margin of 30.68% and a negative return on equity of 6.37%. The business had revenue of $185.61 million for the quarter, compared to analyst estimates of $150.93 million. During the same period last year, the company posted ($0.24) earnings per share. The company’s quarterly revenue was up 49.6% compared to the same quarter last year. On average, research analysts forecast that Glaukos Corporation will post -0.32 earnings per share for the current year. Wall Street Analyst Weigh In Several analysts recently issued reports on GKOS shares. Truist Financial lifted their target price on Glaukos from $180.00 to $215.00 and gave the company a “buy” rating in a research note on Thursday, July 30th. Needham & Company LLC upped their price target on Glaukos from $150.00 to $201.00 and gave the stock a “buy” rating in a research note on Thursday, July 30th. Wells Fargo & Company increased their price objective on shares of Glaukos from $138.00 to $178.00 and gave the company an “overweight” rating in a report on Thursday, July 30th. BTIG Research lifted their price objective on shares of Glaukos from $193.00 to $202.00 and gave the company a “buy” rating in a research report on Thursday, August 20th. Finally, Wall Street Zen raised shares of Glaukos from a “hold” rating to a “buy” rating in a report on Saturday, August 1st. Twelve equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $178.08.
View Our Latest Analysis on Glaukos
Insider Transactions at Glaukos In related news, COO Joseph E. Gilliam sold 60,000 shares of the stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $179.74, for a total value of $10,784,400.00. Following the transaction, the chief operating officer owned 72,588 shares of the company’s stock, valued at $13,046,967.12. This represents a 45.25% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Leana Wen sold 525 shares of the firm’s stock in a transaction on Friday, July 31st. The stock was sold at an average price of $167.63, for a total value of $88,005.75. Following the transaction, the director owned 21,092 shares in the company, valued at $3,535,651.96. The trade was a 2.43% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 113,025 shares of company stock worth $19,600,006 in the last ninety days. 5.90% of the stock is owned by company insiders.
About Glaukos (Free Report)
Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.
Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.
Recommended Stories Five stocks we like better than Glaukos Strike a Balance Between Growth and Stability With These 3 Names Ready to Rally Rubrik’s AI Security Bet Could Power the Next Leg Higher Apple’s Foldable iPhone Could Be a Catalyst, But Not a Cure-All Snowflake Is Up Nearly 50% in 2026—What Are Short Sellers Betting Against? Want to see what other hedge funds are holding GKOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Glaukos Corporation (NYSE:GKOS – Free Report).
Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.
Akcie Glaukos po poslední výsledkové zprávě za měsíc přidaly zhruba 8 % a společnost zároveň zvýšila celoroční výhled tržeb na 680–700 milionů USD. Ve 2. čtvrtletí tržby vzrostly o 50 % na 185,6 milionu USD.
A month has gone by since the last earnings report for Glaukos (GKOS - Free Report) . Shares have added about 8% in that time frame, outperforming the S&P 500.
But investors have to be wondering, will the recent positive trend continue leading up to its next earnings release, or is Glaukos due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the latest earnings report in order to get a better handle on the important drivers.
Glaukos Q2 Earnings Beat Estimates on iDose TR GrowthGlaukos reported a second-quarter 2026 adjusted loss of 14 cents per share, narrower than the Zacks Consensus Estimate of a loss of 28 cents by 50%. The figure also improved from the year-ago quarter’s adjusted loss of 24 cents per share.
The GAAP loss per share was 31 cents compared with the prior-year quarter’s reported loss of 34 cents.
GKOS’ Q2 Revenue PerformanceRevenues of $185.6 million increased 50% year over year on a reported basis and 49% at constant currency (cc). The top line surpassed the Zacks Consensus Estimate by 24.1%.
Growth was driven by increasing adoption and utilization of iDose TR, broader interventional glaucoma initiatives across U.S. and international markets, continued expansion of the company’s global commercial infrastructure and early contributions from the Epioxa launch.
Better-than-expected sales growth led the management to raise its guidance for the full year.
Glaukos Posts Broad Segmental GrowthU.S. Glaucoma revenues reached a record $118.5 million, up 64% year over year on a reported basis. The increase reflected expanding iDose TR adoption, higher utilization among active surgeons and continued growth in trained physicians and accounts.
International Glaucoma revenues were $36.6 million, up 17% year over year on a reported basis. Growth was broad-based, supported by international infrastructure investments and contributions from iStent infinite and PRESERFLO.
Corneal Health revenues increased 48% year over year to $30.4 million. Epioxa contributed approximately $11 million in its first full quarter of commercial availability.
Glaukos’ Margins Expand as Loss NarrowsAdjusted gross profit increased 52.3% year over year to $156.9 million. The adjusted gross margin expanded 150 basis points (bps) to 84.5%.
Selling, general and administrative expenses rose 39.2% year over year to $116.1 million. Research and development expenses totaled $51.3 million, up 40.4% from the prior-year quarter. Total operating expenses were $168.9 million, up 40.8% year over year.
The operating loss narrowed to $17.3 million from $22.7 million in the year-ago period. The adjusted operating loss was $7.6 million, narrower than the prior-year quarter’s adjusted operating loss of $16.6 million.
GKOS Strengthens Its Liquidity PositionGlaukos exited the second quarter with $286.2 million in cash, cash equivalents and short-term investments, up from $280.5 million at the end of the first quarter. The company reported no debt.
Cumulative net cash provided by operating activities was $2.3 million against cumulative net cash used in operating activities of $11.5 million in the year-ago period.
Glaukos Raises 2026 Revenue GuidanceGlaukos raised its 2026 revenue guidance. Management now expects net sales in the range of $680 million to $700 million, up from its previous guidance of $620 million to $635 million. The Zacks Consensus Estimate for the same is pegged at $627.6 million.
The loss per share estimate is pinned at 57 cents, implying a 36.7% improvement year over year.
How Have Estimates Been Moving Since Then?It turns out, fresh estimates have trended upward during the past month.
The consensus estimate has shifted 25.93% due to these changes.
VGM ScoresCurrently, Glaukos has a great Growth Score of A, a grade with the same score on the momentum front. However, the stock has a score of F on the value side, putting it in the fifth quintile for value investors.
Overall, the stock has an aggregate VGM Score of B. If you aren't focused on one strategy, this score is the one you should be interested in.
OutlookEstimates have been broadly trending upward for the stock, and the magnitude of these revisions looks promising. Notably, Glaukos has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Performance of an Industry PlayerGlaukos belongs to the Zacks Medical - Instruments industry. Another stock from the same industry, Thermo Fisher Scientific (TMO - Free Report) , has gained 9.4% over the past month. More than a month has passed since the company reported results for the quarter ended June 2026.
Thermo Fisher reported revenues of $11.99 billion in the last reported quarter, representing a year-over-year change of +10.5%. EPS of $6.03 for the same period compares with $5.36 a year ago.
For the current quarter, Thermo Fisher is expected to post earnings of $6.40 per share, indicating a change of +10.5% from the year-ago quarter. The Zacks Consensus Estimate has changed +0.3% over the last 30 days.
Thermo Fisher has a Zacks Rank #3 (Hold) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of D.
Deutsche Bank AG ve 2. čtvrtletí koupila nový podíl ve společnosti Glaukos: 61 957 akcií za zhruba 8,659 mil. USD. Podíl představoval asi 0,11 % společnosti.
Deutsche Bank AG acquired a new stake in Glaukos Corporation (NYSE:GKOS – Free Report) during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 61,957 shares of the medical instruments supplier’s stock, valued at approximately $8,659,000. Deutsche Bank AG owned about 0.11% of Glaukos at the end of the most recent reporting period.
A number of other large investors also recently made changes to their positions in the company. Los Angeles Capital Management LLC bought a new position in shares of Glaukos during the fourth quarter worth approximately $28,000. Larson Financial Group LLC lifted its position in Glaukos by 62.0% during the fourth quarter. Larson Financial Group LLC now owns 345 shares of the medical instruments supplier’s stock worth $39,000 after purchasing an additional 132 shares during the period. Parallel Advisors LLC lifted its position in Glaukos by 159.2% during the first quarter. Parallel Advisors LLC now owns 368 shares of the medical instruments supplier’s stock worth $40,000 after purchasing an additional 226 shares during the period. Farther Finance Advisors LLC grew its stake in Glaukos by 111.4% during the fourth quarter. Farther Finance Advisors LLC now owns 408 shares of the medical instruments supplier’s stock worth $46,000 after buying an additional 215 shares in the last quarter. Finally, CWM LLC grew its stake in Glaukos by 25.2% during the fourth quarter. CWM LLC now owns 710 shares of the medical instruments supplier’s stock worth $80,000 after buying an additional 143 shares in the last quarter. Institutional investors own 99.04% of the company’s stock.
Glaukos Trading Up 0.4% GKOS opened at $185.66 on Monday. The company’s 50 day moving average is $157.38 and its 200-day moving average is $131.72. Glaukos Corporation has a 1-year low of $73.16 and a 1-year high of $191.62. The company has a current ratio of 5.04, a quick ratio of 4.46 and a debt-to-equity ratio of 0.10. The company has a market cap of $10.95 billion, a P/E ratio of -57.13 and a beta of 0.78.
Glaukos (NYSE:GKOS – Get Free Report) last announced its quarterly earnings results on Wednesday, July 29th. The medical instruments supplier reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.07. The company had revenue of $185.61 million for the quarter, compared to analyst estimates of $150.93 million. Glaukos had a negative net margin of 30.68% and a negative return on equity of 6.37%. The firm’s revenue was up 49.6% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.24) EPS. Equities research analysts predict that Glaukos Corporation will post -0.32 earnings per share for the current fiscal year. Analyst Ratings Changes Several brokerages have recently commented on GKOS. Stifel Nicolaus boosted their target price on shares of Glaukos from $175.00 to $190.00 and gave the company a “buy” rating in a research report on Thursday, July 30th. Needham & Company LLC increased their price target on shares of Glaukos from $150.00 to $201.00 and gave the stock a “buy” rating in a research report on Thursday, July 30th. Piper Sandler reissued an “overweight” rating and issued a $195.00 price objective (up from $165.00) on shares of Glaukos in a research note on Thursday, July 30th. JPMorgan Chase & Co. boosted their price objective on shares of Glaukos from $120.00 to $140.00 and gave the company an “overweight” rating in a research report on Thursday, April 30th. Finally, UBS Group began coverage on Glaukos in a research note on Tuesday, July 28th. They set a “neutral” rating and a $150.00 target price for the company. Twelve analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $178.08.
View Our Latest Stock Analysis on GKOS
Insider Activity at Glaukos In other news, COO Joseph E. Gilliam sold 60,000 shares of the stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $179.74, for a total value of $10,784,400.00. Following the completion of the transaction, the chief operating officer directly owned 72,588 shares in the company, valued at approximately $13,046,967.12. This represents a 45.25% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Gilbert H. Kliman sold 2,500 shares of the stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $190.00, for a total value of $475,000.00. Following the completion of the transaction, the director owned 37,406 shares of the company’s stock, valued at $7,107,140. The trade was a 6.26% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 113,025 shares of company stock worth $19,600,006. Corporate insiders own 5.90% of the company’s stock.
Glaukos News Roundup Here are the key news stories impacting Glaukos this week:
Positive Sentiment: BTIG Research raised its price target to $202 from $193 and maintained a “Buy” rating, implying additional upside from the referenced share price. The move reinforces bullish sentiment among analysts. BTIG price target report Positive Sentiment: Zacks Research lifted its FY2026 EPS forecast to a loss of $0.43 from a loss of $0.65, its Q3 2026 estimate to a loss of $0.13 from $0.16, and its Q4 estimate to positive $0.03 from a loss of $0.02. The revisions suggest improving near-term earnings trends. Positive Sentiment: Zacks also raised its FY2027 EPS estimate to $0.45 from $0.38 and its FY2028 forecast to $1.70 from $1.56. Several later-quarter estimates were increased, pointing to expectations that Glaukos will become increasingly profitable as its products scale. Positive Sentiment: Momentum in the iDose TR glaucoma implant and the Epioxa launch is reportedly driving record growth, higher 2026 guidance and expansion of Glaukos’ ophthalmology platform. Zacks growth outlook article Neutral Sentiment: Glaukos recently reported revenue of $185.6 million, up 49.6% year over year, while its $0.14 quarterly loss was narrower than expected. However, the company remains unprofitable, and its current-year consensus EPS forecast is still a loss of $0.35. Negative Sentiment: Director Gilbert H. Kliman sold 2,500 shares for approximately $475,000 at an average price of $190, reducing his direct ownership by 6.26%. He retained 37,406 shares, so the transaction is a modest negative signal rather than a major change in insider alignment. SEC insider selling filing Glaukos Company Profile (Free Report)
Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.
Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.
See Also Five stocks we like better than Glaukos VIG, VYM, and VYMI: Which Vanguard Dividend ETF Is Right for You? 3 Closed-End Funds to Maximize Dividend Payments Rocket Lab’s Sell-Off Is Fading—Is It Finally Safe to Buy? $27 Billion in Buybacks: 3 Stocks Betting Their Strong Runs Aren’t Over
Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.
Glaukos zvýšil výhled tržeb na rok 2026 na 680–700 milionů USD, když ve 2. čtvrtletí tržby vzrostly o 50 % na 185,6 milionu USD. Hrubá marže dosáhla zhruba 85 %.
Key Takeaways Glaukos is scaling iDose TR rapidly, with U.S. glaucoma sales up 64% to $118.5 million. Epioxa is adding a second growth pillar as Corneal Health revenues climbed 48% to $30.4 million.Glaukos raised 2026 revenue guidance to $680-$700 million and gross margin reached about 85%. Glaukos Corporation’s (GKOS - Free Report) growth prospects are supported by the continued expansion of interventional glaucoma, growing clinical and commercial synergies between iDose TR and iStent infinite, and the potential for long-term operating leverage. However, physician workflow challenges, infrastructure constraints and margin pressure remain key risks.
Shares of this Zacks Rank #3 (Hold) company have gained 63.1% so far this year against the industry’s 8.7% decline. The S&P 500 Index has increased 12.6% in the same time frame.
Glaukos, with a market capitalization of $10.95 billion, is a leading ophthalmic medical technology and pharmaceutical company. The company has a trailing four-quarter average earnings surprise of 25.87%.
Image Source: Zacks Investment Research
Positive Factors Driving ProspectsiDose TR Is Rapidly Scaling Into a Major Revenue Engine: Glaukos' iDose TR franchise is rapidly changing the company's revenue profile, with U.S. glaucoma sales rising 64% year over year to $118.5 million in the second quarter and iDose contributing approximately $74 million. The strong adoption reflects growing surgeon interest, expanding trained accounts and increasing utilization across commercial and Medicare Advantage populations.
Management now expects iDose revenues of roughly $275-$280 million in 2026, while maintaining confidence in continued penetration of interventional glaucoma. The platform's growing body of clinical evidence, including 24 peer-reviewed publications and multiple Phase IV studies, should further support physician adoption and establish iDose as an important alternative to chronic topical glaucoma therapy.
Epioxa Launch Opens a New High-Value Growth Opportunity: Epioxa is establishing a second major growth pillar for Glaukos following iDose's rapid commercialization. Corneal Health revenues increased 48% to $30.4 million in the second quarter, including approximately $11 million from Epioxa, despite the product being in the early stages of its launch. Epioxa is the first FDA-approved epithelium-on corneal cross-linking therapy for keratoconus, which offers a differentiated clinical proposition versus legacy epi-off treatment.
Glaukos has already established access pathways covering more than 125 million commercial lives, while its treatment-center network reaches approximately 85% of the U.S. population and is expected to approach 95%. These developments provide substantial infrastructure for accelerating patient adoption.
Higher Sales Outlook and Margin Expansion Look Encouraging: Glaukos is demonstrating meaningful operating leverage as higher-margin iDose and Epioxa products become a larger portion of revenue. The second-quarter consolidated sales increased 50% to $185.6 million, prompting management to raise full-year 2026 revenue guidance to $680-$700 million, $60-$65 million above the previous outlook.
Gross margin reached approximately 85%, up about 90 basis points sequentially, with management expecting additional modest expansion as iDose and Epioxa gain mix share. This combination of rapid top-line growth and favorable product mix should improve the company's earnings profile over time. Management also expects operating expenses of approximately $600 million for 2026 while continuing to invest in commercial infrastructure and R&D.
Diversified Pipeline Boosts Growth Potential: Beyond iDose and Epioxa, Glaukos is developing a broad pipeline across five novel therapeutic platforms, reducing its long-term dependence on any single product. The company is advancing iDose TREX in Phase IIb/III, iDose TRIO toward a targeted 2027 approval, a customized topographically guided iLink therapy toward Phase III, iStent infinite and PRESERFLO MicroShunt programs, and a retinal therapy for wet AMD.
The company also expects to introduce its keratoconus screening device later in 2026. If these programs progress successfully, they could expand Glaukos' addressable markets across glaucoma, corneal disease, retinal disorders and ocular surface conditions, reinforcing its transition toward a diversified ophthalmology platform.
Key ChallengesMedicare Coverage Uncertainty Could Restrict iDose's Potential: The most significant risk to Glaukos' iDose growth trajectory remains Medicare reimbursement and coverage policy. Five of seven Medicare Administrative Contractors issued proposed local coverage determinations during the second quarter. Management has acknowledged meaningful debate ongoing around proposed eligibility criteria and step-edit requirements involving topical drops and selective laser trabeculoplasty.
Although Glaukos expects the final policies to become more favorable, there is no statutory timeline for the next step. A restrictive final LCD could limit physician discretion, delay patient access and reduce the addressable Medicare population. Because iDose is already becoming a major revenue contributor, unfavorable coverage decisions could have an outsized impact on the company's future growth expectations.
Epioxa Could Experience a Temporary Revenue Volatility: Epioxa's commercial trajectory faces a near-term reimbursement transition that could create volatility in reported growth. Its permanent, product-specific J-code became effective July 1, 2026, but management expects providers and its specialty-pharma partner to need time to operationalize the new reimbursement process.
At the same time, the previous Photrexa reimbursement mechanism is being phased out. Management specifically warned that these changes could create uncertainty in the third quarter, potentially disrupting the strong momentum established during the second quarter. Although Glaukos expects the issue to be largely resolved by the fourth quarter, the temporary revenue disruption could make quarterly comparisons less predictable and obscure the underlying pace of Epioxa adoption.
International Glaucoma Growth Faces Headwinds: Glaukos' international glaucoma franchise remains healthy, but its growth outlook incorporates several emerging challenges. International glaucoma revenues increased 17% reportedly and 16% on a constant-currency basis in the second quarter. However, management expects new competitive product trialing to create headwinds across certain major markets.
Reimbursement pressure has emerged in Germany and Switzerland, while foreign-exchange tailwinds are expected to disappear over the second half. Although PreserFlo, iStent infinite and broader MIGS adoption should offset some pressure, the combination of competition, reimbursement changes and less favorable currency translation could moderate international growth. Management nevertheless expects low-to-mid-teens growth for the full year, implying a stronger second-half execution requirement.
Estimate TrendThe Zacks Consensus Estimate for 2026 revenues is pegged at $627.6 million, indicating a 36% improvement from the previous year’s level.
The consensus mark for loss per share is pinned at 35 cents, indicating a 61.1% improvement from the year-ago reported number. The consensus estimate for loss per share has narrowed 38.6% in the past 30 days.
Stocks to ConsiderSome better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , West Pharmaceutical (WST - Free Report) and The Cooper Companies (COO - Free Report) .
Globus Medical, currently sporting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
West Pharmaceutical, carrying a Zacks Rank #2 (Buy) at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.
WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 17.4%.
The Cooper Companies, carrying a Zacks Rank #2 at present, reported a second-quarter fiscal 2026 adjusted EPS of $1.21, which beat the Zacks Consensus Estimate by 10%. Revenues of $1.08 billion beat the Zacks Consensus Estimate by 2.6%.
COO has an estimated long-term earnings growth rate of 8.3%. COO’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 5.8%.
Glaukos (GKOS - Free Report) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to a loss of $0.24 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of +50.00%. A quarter ago, it was expected that this glaucoma treatments developer would post a loss of $0.3 per share when it actually produced a loss of $0.18, delivering a surprise of +40%.
Over the last four quarters, the company has surpassed consensus EPS estimates three times.
Glaukos, which belongs to the Zacks Medical - Instruments industry, posted revenues of $185.61 million for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 24.10%. This compares to year-ago revenues of $124.12 million. The company has topped consensus revenue estimates four times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Glaukos shares have added about 34% since the beginning of the year versus the S&P 500's gain of 8.5%.
What's Next for Glaukos?While Glaukos has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Glaukos was unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.16 on $154.92 million in revenues for the coming quarter and -$0.57 on $627.64 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Instruments is currently in the bottom 39% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Another stock from the same industry, Hyperfine, Inc. (HYPR - Free Report) , has yet to report results for the quarter ended June 2026. The results are expected to be released on August 6.
This company is expected to post quarterly loss of $0.09 per share in its upcoming report, which represents a year-over-year change of +25%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
Hyperfine, Inc.'s revenues are expected to be $4.23 million, up 56.7% from the year-ago quarter.
Akcie Glaukos (GKOS) od konce května vzrostly o 45,7 % díky pozitivním komentářům k iDose TR a zmírnění obav z omezení úhrady Medicare. V 1. čtvrtletí firma utržila z iDose TR 54 milionů USD.
Key Takeaways GKOS rallied after positive iDose TR commentary eased concerns over proposed Medicare coverage restrictions.GKOS reported $54M in first-quarter iDose TR sales and expects sequential growth in the second quarter.Glaukos is expanding with Epioxa adoption and a broad ophthalmology pipeline supporting long-term growth. Shares of Glaukos (GKOS - Free Report) have surged 45.7% since the end of May. The stock has outpaced the industry’s 4% gain and the S&P 500 Index’s 0.9% decline.
GKOS stock witnessed a sharp rally after the company announced better-than-expected first-quarter top and bottom-line figures on April 29. However, the stock pared all its gains in May amid uncertainty surrounding the proposed Local Coverage Determination (LCD) for its glaucoma therapy, iDose TR, by Medicare Administrative Contractors (MACs).
The MACs have proposed providing coverage for iDose only to patients who have failed both selective laser trabeculoplasty (SLT) and two topical medications. The proposal also restricts the concurrent use of iDose TR with minimally invasive glaucoma surgery (MIGS) procedures and limits re-administration of iDose TR to once every two years. These proposed restrictions could hurt the drug's commercial prospects.
However, Glaukos management seemed confident about receiving an exclusion or modification on some or all of these restrictions in the final LCD draft, while presenting at several investor conferences held during the end of May or early June. The company is focusing on promoting iDose TR as first-line treatment for ocular hypertension.
One-Month Performance
Image Source: Zacks Investment Research
GKOS management also stated that the market opportunity for iDose TR remains significant despite the proposed restrictions, driven by the rising number of glaucoma cases, and reaffirmed its guidance for 2026 and 2027. The company also believes that many patients are ineligible for SLTs or topical medications or both. GKOS is conducting a phase 4 study to evaluate the use of iDose TR with MIGS procedure, which has demonstrated promising results so far.
Several analysts also believe that the proposed restrictions for iDose TR in the proposed LCDs will have a minimal impact on its sales going forward. They expect a sizable pool of patients who have undergone selective laser trabeculoplasty (SLT) over the past decade to remain eligible for iDose TR.
The recent rally in Glaukos shares can be primarily attributed to investor enthusiasm following the positive commentary on iDose TR. The company recorded $54 million in iDose TR sales during the first quarter of 2026. GKOS expects sales of the therapy to grow sequentially in the second quarter as well.
Other Factors Supporting the Rally
Rising Epioxa Adoption:Apart from iDose TR, Epioxa is emerging as Glaukos' next major growth engine, with management reporting an encouraging commercial launch despite being in its earliest phase. The company has rapidly built a treatment network covering nearly 65% of the U.S. population, with visibility to expand coverage to roughly 95%.
Reimbursement momentum is strengthening, supported by access pathways covering more than 100 million commercial lives. The drug is covered by four of the five largest U.S. payers and received a permanent J-code effective July 2026. Combined with direct-to-consumer awareness campaigns and physician education initiatives, these developments position Epioxa to meaningfully expand the underpenetrated keratoconus treatment market over time.
Strong Pipeline:Glaukos continues to differentiate itself through one of ophthalmology's broadest innovation pipelines, with 13 publicly disclosed programs spanning glaucoma, corneal disorders, retinal diseases and ocular surface therapies. Beyond commercial products like iDose TR and Epioxa, the company is advancing iDose TREX, iStent infinite for earlier-stage glaucoma, and PRESERFLO MicroShunt, iLution for Demodex blepharitis.
The company plans to initiate studies on next-generation iLink technologies and a keratoconus screening device later this year. Management also highlighted promising early-stage retinal assets and multiple Phase 4 studies that could expand reimbursement, strengthen clinical evidence and create additional label-expansion opportunities, supporting sustainable long-term growth beyond its current revenue drivers.
Key Challenges
Despite strong execution, Glaukos faces several operational challenges that could moderate near-term growth. Apart from uncertainty surrounding iDose TR LCDs, Epioxa's launch remains constrained by reimbursement complexity until the permanent J-code becomes fully operational, resulting in temporary claims-processing delays and slower physician adoption.
The company also expects international glaucoma growth to decelerate due to increasing competitive product launches and fading foreign-exchange tailwinds. Furthermore, management plans to accelerate investments in commercial infrastructure, patient awareness and direct-to-consumer initiatives, which will keep operating expenses elevated and delay margin expansion.
In addition, successful commercialization depends on increasing keratoconus diagnosis rates and expanding physician adoption, requiring sustained investment in education, payer engagement and market development before Epioxa can fully realize its long-term billion-dollar revenue potential.
A Glance at GKOS’ Estimates
The Zacks Consensus Estimate for GKOS’ 2026 loss per share is pinned at 57 cents, implying a year-over-year improvement of 36.7%. The Zacks Consensus Estimate for 2027 earnings per share is pegged at 47 cents, implying growth of 181% year over year. In the past 60 days, the consensus mark for the company's earnings has remained stable.
Revenues for 2026 are projected to grow 23.7% to $627.6 million and another 26.6% to $794.3 million in 2027.
Image Source: Zacks Investment Research
GKOS’ Zacks Rank and Stocks to Consider
Currently, Glaukos has a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Veracyte (VCYT - Free Report) , West Pharmaceutical (WST - Free Report) and Intuitive Surgical (ISRG - Free Report) .
Veracyte, currently sporting a Zacks Rank #1 (Strong Buy), reported a first-quarter 2026 adjusted earnings per share (EPS) of 52 cents, which surpassed the Zacks Consensus Estimate by 52.94%. Revenues of $139 million beat the Zacks Consensus Estimate by 6.6%. You can see the complete list of today’s Zacks #1 Rank stocks here.
VCYT has an estimated earnings growth rate of 5.1% for 2026 compared with the industry’s 14% growth. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 45.88%.
West Pharmaceutical, currently carrying a Zacks Rank #2 (Buy), reported first-quarter 2026 EPS of $2.13, which beat the Zacks Consensus Estimate by 26.8%. Revenues of $844.9 million surpassed the Zacks Consensus Estimate by 8.5%.
WST has an estimated long-term earnings growth rate of 13.9% compared with the industry’s 9.6% growth. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 19.37%.
Intuitive Surgical, carrying a Zacks Rank of 2 at present, reported first-quarter 2026 adjusted EPS of $2.50, which beat the Zacks Consensus Estimate by 20.2%. Revenues of $2.77 billion surpassed the Zacks Consensus Estimate by 6.2%.
ISRG has a long-term estimated growth rate of 14.3% compared with the industry’s 12.5% growth. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%
